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Abstract
Background: High fat diets are implicated in the pathogenesis of metabolic syndrome, obesity and renal disease.
Previous studies have revealed that high fat diets promote vascular calcification in uremic rats. Moreover, vitamin E
has been shown to prevent uremic calcifications in genetically obese Zucker rats fed standard diet. The objective of
this study was to investigate the influence of vitamin E supplementation on the development of extraskeletal
calcifications in non-obese (wild type) uremic rats fed high fat diets.
Methods: Wistar rats (n = 32) were preconditioned by feeding either a normal (NF) or high fat (HF) diet for
45 days and subsequently were subjected to 5/6 nephrectomy (Nx). Just before performing the first Nx step,
a blood sample (Pre-Nx) was obtained. After Nx rats were switched to a diet with 0.9% phosphorus and
supplemented with calcitriol. Also, after Nx, half of the rats from each group (NF and HF) were treated with
vitamin E (VitE) in the diet (30,000 mg/kg) and the other half were maintained on basic VitE requirements
(27 mg/kg). Thus, rats were allotted to four experimental groups: Nx-NF (n = 8), Nx-NF-VitE (n = 8), Nx-HF (n = 8) and
Nx-HF-VitE (n = 8). At the time of sacrifice (day 66), blood and tissue samples were obtained.
Results: Feeding a HF diet for 45 days did not increase body weight but elicited hyperglycemia, hypertriglyceridemia,
an increase in plasma fibroblast growth factor 23 and a reduction in plasma calcitriol concentrations. After Nx, rats fed
HF diet showed substantial extraskeletal calcification with aortic calcium content that was higher than in rats fed NF
diet. Supplementation with VitE significantly (p < 0.05) reduced aortic (from 38.4 ± 8.8 to 16.5 ± 1.4 mg/g), gastric (from
5.6 ± 2.7 to 1.2 ± 0.4 mg/g) and pulmonary (from 1.8 ± 0.3 to 0.3 ± 0.2 mg/g) calcium content in rats on HF diets.
Conclusions: Uremic rats fed HF diets developed more severe extraosseous calcifications than their normocaloric-fed
counterparts and dietary VitE supplementation protected against uremic calcifications in rats fed HF diets. Thus, eating
energy-rich foods should be discouraged in patients with renal disease and their deleterious effect may be ameliorated
with adequate antioxidant supply.
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Background
Energy-dense food with a high fat content is implicated
in the pathogenesis of obesity and metabolic syndrome
(OB/MS), a significant and growing health problem both
in Western and developing countries [1, 2]. The mecha-
nisms involved in the pathogenesis of OB/MS are complex
and include genetic predisposition, sedentary lifestyle and
excesive intake of sugar- and fat rich foods [3, 4]. The rela-
tionship between OB/MS and renal disease is well known
and can be explained by a variety of indirect mechanisms,
including hypertension and type II diabetes [5, 6], and
direct mechanisms, like increased glomerular capillary
wall tension, changes in podocytes, down-regulation of
the Sirt 1-adiponectin axis, etc. [7].
However, the influence of OB/MS on vascular calcifica-
tions (VC), one of the major contributors to cardiovascular
mortality in patients with chronic kidney disease (CKD) [8],
has not been studied with detail. When subjected to neph-
rectomy, obese Zucker rats have been reported to develop
more severe extraskeletal calcifications than lean Zucker
rats. In this experimental model, the influence of OB/MS
on calcifications seems to be partly mediated by oxidative
stress and calcifications can be prevented by treatment with
vitamin E (VitE) [9].
Moreover, we have recently shown that uremic rats
fed high fat (HF) diets also develop more severe VC than
their counterparts fed normal fat (NF) diets. Phosphorus
(P) retention, secondary to renal klotho and fibroblast
growth factor 23 (FGF23) dysregulation, seems to be
implicated in the procalcifying effect of HF diet [10]. In
patients with CKD, elevated serum P plays a major role
in the development of VC [11]. High extracellular P
concentrations promote VC through a series of mecha-
nisms, including phenotypic transdifferentiation of vas-
cular smooth muscle cells (VSMCs) to osteogenic cells
and increased serum calcium (Ca)xP product, which
facilitates the deposition of Ca salts [12, 13]. Since high
P also has been reported to promote oxidative stress in
VSMCs [14], it would be important to determine whether
antioxidant therapy with VitE is able to ameliorate calcifi-
cations in uremic rats fed a diet rich in fat.
We hypothesized that, as already shown in the model
of genetic-obese Zucker rat, supplemental VitE might
have a beneficial effect on uremic VC in non-obese wild
type rats fed energy-dense diets. Thus, the objective of
this study was to investigate the influence of VitE sup-
plementation on uremic VC in rats fed HF diets.
Methods
Animals and surgical procedures
Three months-old Wistar rats (n = 32), provided by the
Animal Housing Facilities of the University of Cordoba
(Cordoba, Spain), were housed with a 12 h/12 h light/
dark cycle, and given ad libitum access to a standard diet
with normal Ca = 0.6% and P = 0.6%. Uremia was in-
duced by 5/6 nephrectomy (Nx), a two-step procedure
that reduces the original renal mass by five-sixths.
Briefly, animals were anesthetized using xylazine (5 mg/
kg, ip) and ketamine (80 mg/kg, ip). For the first step of
the 5/6 Nx, a 5- to 8-mm incision was made on the left
mediolateral surface of the abdomen. The left kidney
was exposed, and the two poles (2/3 of renal mass) were
ablated. The kidney was inspected and returned to an
anatomically neutral position within the peritoneal cav-
ity. The abdominal wall and skin incisions were closed
with sutures, and the rat was placed back into its home
cage. After 1 week of recovery, in the second step, the
animal was reanesthetized and a 5- to 8-mm incision
was made on the right mediolateral surface of the abdo-
men. The right kidney was exposed and unencapsulated,
the renal pedicle was clamped and ligated, and the kid-
ney was removed. The ligated pedicle was returned to a
neutral anatomical position and the abdomen and skin
incisions closed with suture materials. Fentanyl (0.2 mg/
kg, ip) was used as analgesic agent. After the second sur-
gery, the mineral content of the diet was changed to a
diet containing Ca = 0.6% and P = 0.9% (Altromin Spe-
zialfutter GmbH, Germany). Rats were supplemented
with calcitriol, 80 ng/kg ip every other day (Calcijex,
Abbot, Madrid, Spain). This dose of calcitriol has been
previously shown to be effective in controlling secondary
hyperparathyroidism. Independent of their P content, diets
had either a normal fat content (NF diet) with a 5% fat con-
centration that provided Metabolizable Energy = 3518 kcal/
kg (Altromin C 1000, Altromin Spezialfutter GmbH,
Germany) or a high fat content (HF diet) with a 35% fat
concentration that provided Metabolizable Energy =
5241 kcal/kg (Altromin C 1090–60, Altromin Spezialfutter
GmbH, Germany). Sacrifice was performed by aortic punc-
ture and exsanguination of the anesthetized (sodium thio-
pental, ip) rat. All experimental protocols were reviewed
and approved by the Ethics Committee for Animal Re-
search of the University of Cordoba (Cordoba, Spain).
All protocols were carried out in accordance with the
approved guidelines. They followed the guidelines laid
down by the Higher Council of Scientific Research of Spain
following the normal procedures directing animal welfare
(Real Decreto 223/88, BOE of 18 of March) and adhered to
the recommendations included in the Guide for Care and
Use of Laboratory Animals (US Department of Health and
Human Services, NIH) and European laws and regulations
on protection of animals, under the advice of specialized
personnel.
Experimental design
Sixteen rats were maintained for 45 days on NF diet and
16 rats on HF diet (both diets with 0.6% Ca and 0.6% P).
At day 45, rats were subjected to Nx. Just before
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performing the first Nx step, a blood sample (Pre-Nx)
was obtained from these 32 rats to assess the influence
of the caloric content of the diet on metabolic status
without the confounding effects of uremia. After the sec-
ond step of Nx, at day 52, rats were switched to a 0.9% P
diet and treated with calcitriol, as described above. The
caloric content of the diets was maintained as before
and the rats continued eating either NF or HF till the
end of the experiments. Also, after Nx, half of the rats
from each group (NF and HF) were supplemented with
VitE in the diet (30,000 mg/kg) and the other half were
maintained on basic VitE requirements (27 mg/kg). Thus,
the four experimental groups were: Nx-NF (n = 8), Nx-
NF-VitE (n = 8), Nx-HF (n = 8) and Nx-HF-VitE (n = 8).
Rats were scheduled for sacrifice at day 80, four weeks
after Nx, but due to the rapid deterioration experienced
by the rats fed HF, sacrifice was performed at day 66
(Fig. 1).
Assessment of vascular calcification
Following sacrifice, the thoracic aorta, stomach and lungs
were dissected and processed to study mineral content.
Vascular and soft tissue calcification was studied by hist-
ology and by measuring the tissue Ca content. Samples of
the abdominal aorta, the right lung, and the stomach were
fixed in 10% buffered formalin and subsequently sectioned
and stained for mineralization by the Von Kossa method.
Another portion of the aorta was demineralized in 10%
formic acid, and the arterial tissue Ca content was mea-
sured in the supernatant. Quantification of tissue mineral
content was performed as described previously [15].
Briefly, the stomach and the left lung from each rat were
placed into separate 50-ml tubes. Twenty milliliters of
150 mM HCl was added to each tube. The tubes were
mixed by inversion for 24 h at room temperature, and
Ca was measured in the acid extract. Ca concentration
in the acid extracts was measured by spectrophotom-
etry (BioSystems SA, Barcelona, Spain).
Blood chemistries
Blood for chemistry analyses was obtained either in anes-
thetized (inhaled sevofluorane) rats, from the jugular vein,
or at the time of sacrifice (thiopental anesthesia plus exan-
guination), from the abdominal aorta. Blood for measure-
ments of ionized Ca levels was collected in heparinized
syringes and immediately analyzed using a Ciba-Corning
634 ISE Ca2+/pH Analyzer (Ciba-Corning, Essex, England).
Afterwards, plasma was separated by centrifugation and
stored at −20° C until assayed. Plasma creatinine, P, glucose,
total cholesterol, high density lipoprotein (HDL) choles-
terol, low density lipoprotein (LDL) cholesterol and triglyc-
erides were measured by spectrophotometry (BioSystems
SA, Barcelona, Spain). ELISA tests were used to quan-
tify plasma FGF23 (Kainos Laboratories, Tokyo, Japan)
and parathyroid hormone (PTH) (Immutopics, San
Clemente, CA). Radioimmunoassay was used in plasma
samples to determine insulin (Millipore, St. Charles,
MO, USA), leptin (Millipore, St. Charles, MO, USA) and
calcitriol (Immunodiagnostic Systems Ltd., Boldon, UK).
Statistics
Values are expressed as the mean ± standard error. The
difference between means for two different groups was
determined by t-test; the difference between means for
three or more groups was assessed by Analysis of Vari-
ance. Fisher Least Significant Difference test was used as a
post-hoc procedure. A correlation study was carried out
using the Pearson test. p < 0.05 was considered significant.
Results
Before inducing uremia, body weight was similar in rats
fed NF (198.8 ± 5.6 g) and in rats fed HF (202.5 ± 5.1 g).
The rats that were fed HF diets did not increase body
Fig. 1 Diagram of the experimental design. Nx = 5/6 nephrectomy, NF = normal fat diet (5% fat), HF = high fat diet (35% fat), VitE = vitamin E
added to the diet (30,000 mg/kg)
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weight because they ingested less food: 10.7 ± 0.4 g/day
than the rats fed NF diets: 13.0 ± 0.5 g/day. The differ-
ences in food intake between NF and HF diets were sig-
nificant (p < 0.05). After Nx, body weight decreased both
in rats fed NF (189.4 ± 3.5 g) and in rats fed HF (178.5 ±
3.1 g).
No differences in plasma creatinine were found between
the rats that were fed NF and HF diets prior to Nx. How-
ever, rats fed HF diets had significantly higher glucose
(134.6 ± 2.6 vs 125.4 ± 1.8 mg/dl), LDL cholesterol (6.6 ± 0.3
vs 5.0 ± 0.4 mg/dl) and triglycerides (72.9 ± 5.9 vs 50.3 ±
3.2 mg/dl). Plasma concentrations of FGF23 were higher in
rats fed HF diet, 926 ± 121 pg/ml, than in rats fed NF diet,
217 ± 17 pg/ml, p < 0.05. No differences in plasma leptin
and PTH were found between rats fed NF and HF diet.
Prior to Nx, plasma concentrations of calcitriol were de-
creased in rats fed HF, 11.3 ± 1.2 pg/ml, when compared
with rats fed NF, 77.7 ± 9.2 pg/ml, p < 0.001.
Nephrectomy resulted in an increase in creatinine in
all experimental groups. At the time of sacrifice plasma
creatinine was significantly higher in rats fed HF diet
(1.8 ± 0.2 mg/dl) than in rats fed NF diet (1.3 ± 0.1 mg/dl).
Treatment with VitE reduced plasma creatinine and the
difference was significant in the rats fed NF diet (1.0 ±
0.1 mg/dl). Although plasma Ca was reduced in all uremic
rats, higher values were recorded in the rats fed NF diet
(1.14 ± 0.02 mmol/l). Plasma P was higher in the rats fed
HF diet, 10.8 ± 1.4 mg/dl vs 6.6 ± 1.0 in the rats fed NF
diet. VitE supplementation reduced P levels to 8.5 ±
0.5 mg/dl (HF diet) and 4.2 ± 0.4 mg/dl (NF diet). When
compared with the non-uremic controls, Nx rats had
higher glucose, insulin and cholesterol (total, LDL and
HDL) concentrations. Plasma triglycerides were de-
creased in Nx groups and rats receiving supplemental
VitE had the lowest triglycerides levels (p < 0.05 vs non-
supplemented rats). As expected, the phosphaturic fac-
tor FGF23 was increased in all Nx groups and was
higher in rats fed HF diets than in rats fed NF diets.
Plasma PTH values, which in Nx rats were controlled
by treatment with calcitriol, were not influenced by either
diet caloric content or VitE supplementation. Uremic rats,
that were treated with calcitriol, had mean plasma calci-
triol concentrations ranging from 48.5 to 64.6 pg/ml and
no significant differences were found between the four
experimental groups (Table 1).
Rats fed HF diet showed substantial aortic calcification
with calcium content that was significantly higher than
in rats fed NF diet (38.4 ± 8.8 mg/g tissue vs 8.7 ± 4.2 mg/g
tissue, p < 0.001). Supplementation with VitE reduced aortic
calcium content in rats on HF diets to 16.5 ± 1.4 mg/g tis-
sue (p = 0.018). Differences in aortic calcification between
experimental groups were also evident by histology with
Von Kossa staining (Fig. 2).
Mineral deposition in stomach and lung was less severe
than in aorta and only was obvious in rats fed HF. Thus
Nx-HF rats had a calcium content of 5.6 ± 2.7 mg/g in the
stomach and 1.8 ± 0.3 mg/g in the lungs. Dietary VitE
supplementation resulted in a significant decrease in
soft tissue calcification both in stomach, 1.2 ± 0.4 mg/g
(p = 0.024), and in the lungs, 0.3 ± 0.2 mg/g (p < 0.001).
Von Kossa staining of stomach and lung tissue sections
also demonstrated the presence of calcifications in rats
fed HF and their attenuation with dietary vitamin E
(Figs. 3 and 4).
Discussion
This study was designed to investigate the influence of
supplementing VitE on the development of extraskeletal
calcifications in uremic rats fed diets with HF content.
Our results confirm a previous report of a pro-calcifying
Table 1 Blood biochemistry from the study rats
PreNx-NF PreNx-HF Nx-NF Nx-NF-VitE Nx-HF Nx-HF-VitE
Creatinine (mg/dl) 0.6 ± 0.1a 0.5 ± 0.1a 1.3 ± 0.1b 1.0 ± 0.1d 1.8 ± 0.2c 1.5 ± 0.2b
Calcium (mmol/l) 1.30 ± 0.02a 1.29 ± 0.02a 1.14 ± 0.02b 1.04 ± 0.02c 1.01 ± 0.02c 1.00 ± 0.02c
Phosphorus (mg/dl) 3.9 ± 0.4a 4.1 ± 0.2a 6.6 ± 1.0a 4.2 ± 0.4a 10.8 ± 1.4b 8.5 ± 0.5b
Glucose (mg/dl) 125.4 ± 1.8a 134.6 ± 2.6b 167.8 ± 5.6c 165.3 ± 5.9c 158.2 ± 6.4c 145.0 ± 2.3b
Insulin (ng/ml) 0.21 ± 0.04a 0.16 ± 0.02a 0.75 ± 0.18b 0.52 ± 0.09b 0.32 ± 0.14a 0.71 ± 0.21b
Total Cholesterol (mg/dl) 60.2 ± 2.2a 64.5 ± 3.0a 114.4 ± 6.6b 68.8 ± 6.8a 113.2 ± 5.4b 117.5 ± 10.6b
LDL Cholesterol (mg/dl) 5.0 ± 0.4a 6.6 ± 0.3b 7.6 ± 1.3b 4.6 ± 0.6a 9.6 ± 1.6c 10.5 ± 2.1c
HDL Cholesterol (mg/dl) 23.1 ± 1.0a 25.9 ± 1.9a 44.6 ± 2.0b 32.8 ± 2.2c 48.8 ± 3.7b 44.5 ± 4.4b
Triglycerides (mg/dl) 50.3 ± 3.2a 72.9 ± 5.9b 32.6 ± 3.2c 14.1 ± 1.2d 35.2 ± 3.5c 48.3 ± 10.7a
FGF23 (pg/ml) 217 ± 17a 926 ± 121b 8984 ± 2333c 5055 ± 1588c 20492 ± 3906d 24579 ± 7879d
Leptin (ng/ml) 1.4 ± 0.2a 1.4 ± 0.2a 0.7 ± 0.3b 1.4 ± 0.4a 1.8 ± 0.4a 0.8 ± 0.5a
PTH (pg/ml) 70.9 ± 7.6a 55.1 ± 2.5a 59.4 ± 3.9a 59.3 ± 4.2a 64.3 ± 6.9a 71.1 ± 14.2a
Calcitriol (pg/ml) 77.7 ± 9.2a 11.3 ± 1.2b 54.3 ± 8.7a 48.5 ± 6.9a 64.6 ± 5.1a 48.7 ± 12.9a
For each parameter, values with different superscript are significantly (p < 0.05) different
Rios et al. BMC Nephrology  (2017) 18:374 Page 4 of 8
effect of HF diets in uremic rats and demonstrate that
dietary VitE supplementation protects against uremic
calcifications in rats fed HF diets.
During the study the rats fed HF adapted food consump-
tion to maintain a caloric intake similar to rats fed NF
(around 50 kcal/day), thus no increase in body weight and
plasma leptin concentrations was observed in rats fed HF.
This allowed to study the effect of the fat content of the
diet independent of obesity-mediated mechanisms (e.g. adi-
pokines and other inflammatory mediators released by fat
tissue). At the time of Nx the animals fed HF diet were not
obese but they showed biochemical signs of metabolic syn-
drome: hyperglycemia, hypertriglyceridemia and increased
LDL. At this stage, with a background of metabolic changes
Fig. 2 a Calcium content (mg/g of tissue) in the aortas of rats from the four experimental groups. b Representative von Kossa stained aortic
tissue sections from the same rats where mineral deposits are depicted by the brown pigment. Nx-NF = uremic rats treated with calcitriol (80 ng/kg ip
eod) fed normal fat diet with 0.9% phosphorus (n= 8), Nx-NF-VitE = uremic rats treated with calcitriol (80 ng/kg ip eod) fed normal fat diet with 0.9%
phosphorus and supplemented with vitamin E, 30,000 mg/kg (n= 8), Nx-HF = uremic rats treated with calcitriol (80 ng/kg ip eod) fed a high fat diet with
0.9% phosphorus (n= 8), Nx-HF-VitE = uremic rats treated with calcitriol (80 ng/kg ip eod) fed high fat diet with 0.9% phosphorus and supplemented with
vitamin E, 30,000 mg/kg (n= 8). a p< 0.05 vs Nx-NF, b p< 0.05 vs Nx-HF
Fig. 3 a Calcium content (mg/g of tissue) in the stomachs of rats from the four experimental groups. b Representative von Kossa stained gastric
tissue sections from the same rats where mineral deposits are depicted by the brown pigment. Nx-NF = uremic rats treated with calcitriol (80 ng/kg ip
eod) fed normal fat diet with 0.9% phosphorus (n= 8), Nx-NF-VitE = uremic rats treated with calcitriol (80 ng/kg ip eod) fed normal fat diet with 0.9%
phosphorus and supplemented with vitamin E, 30,000 mg/kg (n= 8), Nx-HF = uremic rats treated with calcitriol (80 ng/kg ip eod) fed a high fat diet with
0.9% phosphorus (n= 8), Nx-HF-VitE = uremic rats treated with calcitriol (80 ng/kg ip eod) fed high fat diet with 0.9% phosphorus and supplemented with
vitamin E, 30,000 mg/kg (n= 8). a p< 0.05 vs Nx-NF, b p< 0.05 vs Nx-HF
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induced by high caloric intake, we had the opportunity to
explore the impact of renal failure on VC and the influence
of VitE.
The dose of vitamin E used in the experiments was
chosen based on previous studies [9]. Rats ingested around
300 mg of vitamin E per day which is the upper limit of
what is considered safe for long term administration of
vitamin E to humans [16]. Although it is difficult to ex-
trapolate the effect of this dose of vitamin E to humans,
none of the side effects described in people after vitamin
E overdose (diarrhea, skin inflammation, hyperglycemia,
hyperlipidemia) were observed in the present study.
Our results confirm previous data showing that pre-
conditioning with HF diet predisposes rats to develop
extraskeletal calcifications associated to renal failure [10].
This finding highlights the potential deleterious effect on
VC of energy-dense diets, even in the absence of obesity.
Moreover, treatment with VitE reduced the severity of
extraskeletal calcifications in rats fed HF. VitE has been
previously shown to be effective in preventing VC in rats
with genetic obesity [9]. The results of the present study
expand these data to a population of non-obese, although
metabolically challenged, rats and demonstrate that obes-
ity per se is not a requisite for the deleterious effect of HF
diets on VC in uremic rats. When compared with a earlier
report in which genetic obese Zucker rats fed a NF diet
were subjected to the same experimental protocol, VC
was much more severe in the wild type rats fed HF diet of
the current study [9]. In fact, the present study was origin-
ally designed to last 4 weeks after Nx (same time frame
than the previous study with Zucker rats) but the rapid
deterioration of the rats fed HF diets required to terminate
the study, for humane reasons, 14 days after Nx.
Although it was not a primary objective of this study,
the data obtained also provide interesting insights about
the role of calcitriol on VC in the context of feeding HF
diets. Prior to Nx, rats fed HF diets had very low plasma
calcitriol concentrations. A decrease in plasma calcitriol,
without changes in plasma calcidiol, has been previously
reported in rats with normal renal function after feeding
HF diets [10]. Since FGF23 is known to decrease calci-
triol synthesis through inhibition of 1-alpha-hydroxylase
activity in the kidney [17], these low calcitriol concentra-
tions have been linked to the increase in FGF23 elicited
by HF diets [10]. In uremic rats calcitriol should be fur-
ther reduced by the decrease in renal mass and by the
elevation in FGF23 secondary to kidney disease [18].
Vitamin D deficiency is associated with cardiovascular
disease [19–21] and calcitriol treatment has been reported
to improve survival of CKD patients [22, 23]. Thus, it could
be speculated that treatment with calcitriol may have bene-
ficial effects on uremic rats fed HF. However, when com-
paring the results of this study with previous data in which
rats fed HF were not treated with calcitriol [10], calcifica-
tions were much more severe after calcitriol treatment.
Therefore, the results of this study demonstrate that even
though rats fed HF diets have very low plasma calcitriol
concentrations, treatment with calcitriol at doses sufficient
to control secondary hyperparathyroidism is clearly dele-
terious. The negative actions of calcitriol are probably
Fig. 4 a Calcium content (mg/g of tissue) in the lungs of rats from the four experimental groups. b Representative von Kossa stained pulmonary
tissue sections from the same rats where mineral deposits are depicted by the brown pigment. Nx-NF = uremic rats treated with calcitriol (80 ng/
kg ip eod) fed normal fat diet with 0.9% phosphorus (n = 8), Nx-NF-VitE = uremic rats treated with calcitriol (80 ng/kg ip eod) fed normal fat diet
with 0.9% phosphorus and supplemented with vitamin E, 30,000 mg/kg (n = 8), Nx-HF = uremic rats treated with calcitriol (80 ng/kg ip eod) fed a
high fat diet with 0.9% phosphorus (n = 8), Nx-HF-VitE = uremic rats treated with calcitriol (80 ng/kg ip eod) fed high fat diet with 0.9% phosphorus
and supplemented with vitamin E, 30,000 mg/kg (n = 8). a p < 0.05 vs Nx-NF, b p < 0.05 vs Nx-HF
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related to an increased P load in animals with impaired P
excretion derived from feeding HF diets [10], which would
override any beneficial effect that restoring plasma calcitriol
concentrations may have on vascular health. In fact, the
data of this study raise the intriguing question of whether
the decrease in plasma calcitriol observed after feeding HF
diets might act as a protective mechanism in rats that
already have difficulty in excreting P.
The decrease in phosphate levels in uremic rats treated
with vitamin E is probably related to the reduction in extra-
skeletal calcification: nephrocalcinosis was less severe in an-
imals treated with vitamin E thus allowing their remnant
kidneys to be more efficient in phosphate excretion.
The mechanisms to explain the detrimental effect of
HF diets on VC are probably multifactorial. In previous
studies with obese Zucker rats we have shown that oxida-
tive stress plays an important role in obesity-associated VC
[9]. The results of the present study also support a role of
oxidative stress in HF diet-induced calcifications, because
treatment with VitE substantially decreased VC. In addition
to any direct pro-oxidant action of feeding HF, HF diet-
induced P retention may also contribute to oxidative stress
[14]. Thus, VitE treatment may help to modulate the ad-
verse pro-oxidant effects of P retention secondary to feed-
ing HF. Nonetheless since the study was performed in an
animal model of uremia, caution should be taken when ex-
trapolating the results to the human situation.
Conclusions
In conclusion, uremic rats fed HF diets develop more se-
vere extraosseous calcifications than their normocaloric-fed
counterparts and dietary VitE supplementation protects
against uremic calcifications in rats fed HF diets. Thus,
eating energy-rich foods should be discouraged in patients
with renal disease and their deleterious effect may be ame-
liorated with adequate antioxidant supply.
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